Brigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 Brigatinib

Product Details
Customization: Available
Powder: Yes
Customized: Customized
Still deciding? Get samples of $ !
Request Sample
Diamond Member Since 2024

Suppliers with verified business licenses

Audited Supplier Audited Supplier

Audited by an independent third-party inspection agency

In-stock Capacity
The supplier has In-stock capacity
Fast Delivery
The supplier can deliver the goods within 15 days
OEM Services
The supplier provides OEM services for popular brands
R&D Capabilities
The supplier has 1 R&D engineers, you can check the Audit Report for more information
to see all verified strength labels (13)
  • Brigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 Brigatinib
  • Brigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 Brigatinib
  • Brigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 Brigatinib
  • Brigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 Brigatinib
  • Brigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 Brigatinib
  • Brigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 Brigatinib
Find Similar Products

Basic Info.

Certification
GMP, ISO 9001, USP, BP
Suitable for
Adult
State
Powder
Purity
>98%
Sample
Available
OEM
Available
MOQ
1kg
Keyword 1
Brigatinib
Keyword 2
Brigatinib Powder
Storage
Dry and Cool Place
Transport Package
Foil Bag/25kg Drum
Specification
98%
Trademark
/
Origin
China
Production Capacity
10000

Product Description

Brigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 Brigatinib

Description
Brigatinib is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.

Name Brigatinib
Grade Pharmaceutical Grade
Appearance White powder
Specification 98%


Function and Application
Brigatinib, also known as AP-26113, is an orally active, potent and selective Dual ALK/EGFR inhibitor. AP26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.

Brigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 BrigatinibBrigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 BrigatinibBrigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 BrigatinibBrigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 BrigatinibBrigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 BrigatinibBrigatinib Powder CAS 1197953-54-0 Pharmaceutical Ap26113 Brigatinib

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier